ALTUM-TECHNOLOGIES
23.3.2023 14:01:33 CET | Business Wire | Press release
Altum Technologies, a Finnish company that has developed a patented method of cleaning technology, has been selected to participate in Chevron Technology Ventures (CTV) Catalyst Program. The deep tech company has developed a market-leading power ultrasound solution that improves process efficiency without stopping production. The collaborative program gives Altum Technologies the platform to further advance and deploy its Zero Process Downtime (ZPD) technology globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005027/en/
Altum Technologies has been selected to participate in Chevron Technology Ventures (CTV) Catalyst Program. The deep tech company has developed a market-leading power ultrasound solution that improves process efficiency without stopping production. (Graphic: Business Wire)
Fouling and scaling are problems in most industrial processes that causeperiodic planned and unplanned shutdowns for difficult and expensive cleaning tasks. Shutting down a company’s operations partially or in whole to manually open up the production process and enable cleaning of the process equipment, is a costly practice that has been accepted as a cost of doing business. Altum’s Zero Process Downtime (ZPD) technology has the ability to minimize maintenance time, decrease energy consumption and the use of hazardous chemicals. Altum’s Ultrasonic climate technology is a patented method that is available today to improve any existing production process.
The solution can be installed and used in almost any production process without stopping the production lines and without making any changes to the existing production equipment. By increasing energy efficiency and reducing the use of harmful chemicals, Altum helps to significantly reduce environmental impacts. The Solar Impulse Foundation has labeled the solution as environmentally positive.
The CTV Catalyst Program is an initiative that was launched in 2017 to accelerate the maturation of early-stage companies that have technology potentially beneficial to the energy industry. Members of the Altum Technologies and CTV teams will work together to set milestones. By meeting those milestones, the Catalyst Program can assist in Altum Technologies growth and implementing the technology to improve process efficiency, reduce CO2 emissions and reduce the use of energy in process industry around the world.
Bo Malmberg, Co-Founder and CCO said: “The support of Chevron, a leader in the energy sector, reinforces the potential of our unique technology and provides a great opportunity to collaborate with one of the leading teams in the Energy Industry. Both Chevron and Altum Technologies are committed to help process industry make their processes more efficient including reducing the use of energy and chemicals.”
About Altum Technologies
Altum, HQ in Helsinki, Finland and founded in 2016, is the first company in the world that can completely control power ultrasound to clean fouling from different type of equipment without stopping production. Our disruptive ZPD technology also minimizes maintenance time, energy consumption and use of hazardous chemicals in these cleaning processes.
About Chevron Technology Ventures
Chevron Technology Ventures (CTV) was launched in 1999 to identify and integrate externally developed technologies and new business solutions with the potential to enhance the way Chevron produces and delivers affordable, reliable, and ever-cleaner energy now and into the future.
For more information: https://www.chevron.com/technology/technology-ventures
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
